Do ESR1-related mutations generate neoantigens in hormone-receptor-positive HER2-negative metastatic breast cancer?

被引：0

作者：

Lopez, M. ^{[1
]}

Spehner, L. ^{[1
]}

Ramseyer, M. ^{[2
]}

Bouard, A. ^{[2
]}

Dobi, E. ^{[1
]}

Curtit, E. ^{[1
]}

Borg, C. ^{[1
]}

Mansi, L. ^{[1
]}

机构：

[1] Hop Jean Minjoz, CHRU Besancon, Team Therapeut Immunomol Canc, Besancon, France

[2] Doubs, UMR1098, Besancon, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.653

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

477P

引用

页码：S382 / S382

页数：1

共 50 条

[41] Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
Rugo, Hope S.
Hortobagyi, Gabriel N.
Piccart-Gebhart, Martine J.
Burris, Howard A.
Campone, Mario
Noguchi, Shinzaburo
Perez, Alejandra T.
Deleu, Ines
Shtivelband, Mikhail
Provencher, Louise
Masuda, Norikazu
Dakhil, Shaker R.
Anderson, Ian
Chen, David
Damask, Amy
Huang, Alan
McDonald, Robert
Taran, Tanya
Sahmoud, Tarek
Baselga, Jose
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
[42] Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
Chaudhary, Lubna N.
Jorns, Julie M.
Sun, Yunguang
Cheng, Yee Chung
Kamaraju, Sailaja
Burfeind, John
Gonyo, Mary Beth
Kong, Amanda L.
Patten, Caitlin
Yen, Tina
Cortina, Chandler S.
Carson, Ebony
Johnson, Nedra
Bergom, Carmen
Tsaih, Shirng-Wern
Banerjee, Anjishnu
Wang, Yu
Chervoneva, Inna
Weil, Elizabeth
Chitambar, Christopher R.
Rui, Hallgeir
BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (03) : 387 - 396
[43] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Shinzaburo Noguchi
Norikazu Masuda
Hiroji Iwata
Hirofumi Mukai
Jun Horiguchi
Puttisak Puttawibul
Vichien Srimuninnimit
Yutaka Tokuda
Katsumasa Kuroi
Hirotaka Iwase
Hideo Inaji
Shozo Ohsumi
Woo-Chul Noh
Takahiro Nakayama
Shinji Ohno
Yoshiaki Rai
Byeong-Woo Park
Ashok Panneerselvam
Mona El-Hashimy
Tetiana Taran
Tarek Sahmoud
Yoshinori Ito
Breast Cancer, 2014, 21 : 703 - 714
[44] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
E. Ciruelos
M. Vidal
E. Martínez de Dueñas
N. Martínez-Jáñez
Y. Fernández
J. A. García-Sáenz
L. Murillo
F. Carabantes
A. Beliera
R. Fonseca
J. Gavilá
Clinical and Translational Oncology, 2018, 20 : 753 - 760
[45] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda
Erul, Enes
Seyyar, Mustafa
Gumusay, Ozge
Bayram, Ertugrul
Demirel, Burcin Cakan
Acar, Omer
Aksoy, Sercan
Baytemur, Naziyet Kose
Sahin, Elif
Cabuk, Devrim
Basaran, Gul
Paydas, Semra
Yaren, Arzu
Guven, Deniz Can
Erdogan, Atike Pinar
Demirci, Umut
Yasar, Alper
Bayoglu, Ibrahim Vedat
Hizal, Mutlu
Gulbagci, Burcu
Paksoy, Nail
Davarci, Sena Ece
Yilmaz, Funda
Dogan, Ozlem
Orhan, Sibel Oyucu
Kayikcioglu, Erkan
Aytac, Ali
Keskinkilic, Merve
Mocan, Eda Eylemer
Unal, Olcun Umit
Aydin, Esra
Yucel, Hakan
Isik, Deniz
Eren, Onder
Uluc, Basak Oyan
Ozcelik, Melike
Hacibekiroglu, Ilhan
Aydiner, Adnan
Demir, Hacer
Oksuzoglu, Berna
Cilbir, Ebru
Cubukcu, Erdem
Cetin, Bulent
Oktay, Esin
Erol, Cihan
Okutur, Sadi Kerem
Yildirim, Nilgun
Alkan, Ali
Selcukbiricik, Fatih
FUTURE ONCOLOGY, 2023, : 727 - 736
[46] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
Tajiri, Wakako
Nakamura, Yoshiaki
Kawasaki, Junji
Koi, Yumiko
Akiyoshi, Sayuri
Koga, Chinami
Tokunaga, Eriko
CANCER RESEARCH, 2024, 84 (09)
[47] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
Hugo Herrscher
Michel Velten
Julie Leblanc
Michal Kalish-Weindling
Cathie Fischbach
Delphine Exinger
Xavier Pivot
Thierry Petit
Breast Cancer Research and Treatment, 2020, 179 : 371 - 376
[48] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora
Potter, David A.
Salkeni, Mohamad A.
Silverman, Paula
Haddad, Tufia C.
Forget, Frederic
Awada, Ahmad
Canon, Jean-Luc
Danso, Michael
Lortholary, Alain
Bourgeois, Hugues
Tan-Chiu, Elizabeth
Vincent, Sylvie
Bahamon, Brittany
Galinsky, Kevin J.
Patel, Chirag
Neuwirth, Rachel
Leonard, E. Jane
Diamond, Jennifer R.
CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
[49] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Walker, Amanda J.
Wedam, Suparna
Amiri-Kordestani, Laleh
Bloomquist, Erik
Tang, Shengui
Sridhara, Rajeshwari
Chen, Wei
Palmby, Todd R.
Zirkelbach, Jeanne Fourie
Fu, Wentao
Liu, Qi
Tilley, Amy
Kim, Geoffrey
Kluetz, Paul G.
McKee, Amy E.
Pazdur, Richard
CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
[50] Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients
Herrscher, Hugo
Velten, Michel
Leblanc, Julie
Kalish-Weindling, Michal
Fischbach, Cathie
Exinger, Delphine
Pivot, Xavier
Petit, Thierry
BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (02) : 371 - 376

← 1 2 3 4 5 →